高级搜索
人黑色素瘤抗原MAGE-3 肿瘤疫苗的构建及其诱导HLA-A *0201 转基因小鼠CTL活性的观察[J]. 肿瘤防治研究, 2007, 34(10): 739-742. DOI: 10.3971/j.issn.1000-8578.900
引用本文: 人黑色素瘤抗原MAGE-3 肿瘤疫苗的构建及其诱导HLA-A *0201 转基因小鼠CTL活性的观察[J]. 肿瘤防治研究, 2007, 34(10): 739-742. DOI: 10.3971/j.issn.1000-8578.900
Construction of MAGE-3 Tumor Vaccine and Its Effect on CTL Activity in HLA-A * 0201 Mice[J]. Cancer Research on Prevention and Treatment, 2007, 34(10): 739-742. DOI: 10.3971/j.issn.1000-8578.900
Citation: Construction of MAGE-3 Tumor Vaccine and Its Effect on CTL Activity in HLA-A * 0201 Mice[J]. Cancer Research on Prevention and Treatment, 2007, 34(10): 739-742. DOI: 10.3971/j.issn.1000-8578.900

人黑色素瘤抗原MAGE-3 肿瘤疫苗的构建及其诱导HLA-A *0201 转基因小鼠CTL活性的观察

Construction of MAGE-3 Tumor Vaccine and Its Effect on CTL Activity in HLA-A * 0201 Mice

  • 摘要: 目的 通过基因工程的方法获得人黑色素瘤抗原MAGE-3的DNA和蛋白疫苗,并观察其对HLA-A*0201转基因小鼠的CTL活性的影响。方法 用RT-PCR的方法,从人黑色素瘤细胞株A375中扩增MAGE-3的cDNA片段,分别将其插入到pcDNA3.1/v5-His真核扣pET32a原核表达载体。将pcDNA-MAGE-3转染B16肿瘤细胞观察其是否能在真核细胞中表达;将pET32a-MAGE-3转化大肠杆菌BL21,经IPTG诱导,SDS-PAGE观察融合蛋白表达情况。并用镍柱亲和层析的方法纯化融合蛋白。然后,采用DNA疫苗初次免疫和蛋白疫苗加强的策略免疫HL-A*0201转基因小鼠,LDH方法检测CTL活性。结果 酶切结果证实,成功地构建了pcDNA-MAGE-3真核表达载体和pET32a-MAGE-3原核表达载体,并在真核细胞B16和原核细胞大肠杆菌中获稳定表达,原核表达产物为融合蛋白且分布于包涵体。用DNA疫苗进行初次免疫,镍柱纯化的融合蛋白加强免疫后,可成功地诱导HL-A*0201转基因小鼠CTL活性。结论 成功地获得了MAGE-3肿瘤抗原,为进一步完善MAGE-3肿瘤疫苗打下了基础。

     

    Abstract: Objective  To obtain the DNA and protein vaccine of human MA GE-3 gene and to observe the effect on CTL activity induction in HLA-A * 0201 mice. Methods  The MAGE-3 gene fragment was obtained by RT-PCR f rom human melanoma A375, and then cloned into the pcDNA3. 1/ V5-His and p ET32a vectors, respectively. The expression vectors were confirmed by rest riction enzyme digestion analysis.The mRNA expression of MAGE-3 gene was detected af ter transfection of the recombinant karyotic expression vector into B16 tumor cells and the expression of p ET-32a-MAGE-3 fusion protein was analyzed in E. coli by SDS-PAGE. The fusion protein was purified by Ni 2+ affinity chromatography. According to the DNA-priming and protein-boosting immune protocol, HLA-A * 0201 transgenic mice were vaccinated with DNA and followed by the protein of MAGE-3. Then, the activity of CTL against specific peptide pulsed by SW480 tumor cells was tested by the method of LDH. Results  Rest riction enzyme digestion analysis showed that the recombinant expression vectors pcDNA3. 1-MAGE-3 and p ET32a-MAGE-3 were successfully const ructed and expressed in B16 or E. coli as a fusion protein. The DNA and purified protein vaccine were obtained respectively and the CTL activity in HLA-A *0201 transgenic mice was obviously observed. Conclusion  MAGE-3 tumor vaccine was obtained successfully, which is helpful for the further study of the MAGE-3 vaccine for tumor therapy.

     

/

返回文章
返回